Low-Dose immunotherapy shows promise against tough colorectal cancer
NCT ID NCT07523763
First seen May 02, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tests a low-dose immunotherapy drug (nivolumab or pembrolizumab) in 30 people with a specific type of advanced colorectal cancer (MSI/dMMR). The goal is to see if the treatment can shrink or eliminate the tumor before surgery. Participants receive the drug for 6 months, and doctors check for complete tumor disappearance using scans and tissue samples.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia
Conditions
Explore the condition pages connected to this study.